key: cord-0822017-96vviv3x
authors: Mungmungpuntipantip, R.; Wiwanitkit, V.
title: COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy
date: 2021-07-09
journal: Clin Oncol (R Coll Radiol)
DOI: 10.1016/j.clon.2021.07.005
sha: abb0e1d7171317219be65511d20ef7740303a2cd
doc_id: 822017
cord_uid: 96vviv3x

nan

Madam d We read with interest Sudan et al.'s Letter 'Optimal timing for COVID-19 vaccination in oncology patients receiving chemotherapy?' [1] . We agree that the immunogenic efficacy of the vaccine is an important issue when vaccinating cancer patients receiving chemotherapy. However, another important issue that should not be forgotten is safety. Sudan et al. [1] have already mentioned the change in immune status, optimal timing for vaccination and risk of serious COVID-19.

Moreover, the administration of a COVID-19 vaccine can induce increased blood viscosity, as there is a rapid production of antibody protein in the plasma after vaccination [2] . In a cancer patient receiving chemotherapy, increased blood viscosity might occur [3] . During chemotherapy there is rapid cell lysis, which may cause a change in the protein component in the plasma [3] . Therefore, there is a possibility that hyperviscosity could occur. It is necessary to monitor the blood viscosity of cancer patients to prevent hyperviscosity. Therefore, it may not be appropriate to give a COVID-19 vaccine during chemotherapy.

Optimal timing for COVID-19 vaccination in oncology patients receiving chemotherapy?

Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19

Blood rheology during chemotherapy in patients with ovarian cancer

0936-6555/Ó 2021 The Royal College of Radiologists

Mungmungpuntipantip R, Wiwanitkit V, COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy